Daiichi Sankyo Company Limited
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 rec… Read more
Market Cap & Net Worth: Daiichi Sankyo Company Limited (DSKYF)
Daiichi Sankyo Company Limited (PINK:DSKYF) has a market capitalization of $43.73 Billion ($43.73 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #579 globally and #461 in its home market, demonstrating a 0.70% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Daiichi Sankyo Company Limited's stock price $23.63 by its total outstanding shares 1851057887 (1.85 Billion).
Daiichi Sankyo Company Limited Market Cap History: 2015 to 2025
Daiichi Sankyo Company Limited's market capitalization history from 2015 to 2025. Data shows growth from $11.25 Billion to $43.73 Billion (16.21% CAGR).
Daiichi Sankyo Company Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Daiichi Sankyo Company Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Daiichi Sankyo Company Limited's market cap is 0.02 times its annual revenue
0.84x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.15x
Daiichi Sankyo Company Limited's market cap is 0.15 times its annual earnings
11.15x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $10.92 Billion | $986.45 Billion | $82.28 Billion | 0.01x | 0.13x |
| 2017 | $14.03 Billion | $955.12 Billion | $53.47 Billion | 0.01x | 0.26x |
| 2018 | $20.40 Billion | $960.20 Billion | $60.28 Billion | 0.02x | 0.34x |
| 2019 | $39.10 Billion | $929.72 Billion | $93.41 Billion | 0.04x | 0.42x |
| 2020 | $62.01 Billion | $981.79 Billion | $129.07 Billion | 0.06x | 0.48x |
| 2021 | $46.10 Billion | $962.52 Billion | $75.96 Billion | 0.05x | 0.61x |
| 2022 | $59.21 Billion | $1.04 Trillion | $66.97 Billion | 0.06x | 0.88x |
| 2023 | $48.38 Billion | $1.28 Trillion | $109.19 Billion | 0.04x | 0.44x |
| 2024 | $60.60 Billion | $1.60 Trillion | $200.73 Billion | 0.04x | 0.30x |
| 2025 | $43.73 Billion | $1.89 Trillion | $295.76 Billion | 0.02x | 0.15x |
Competitor Companies of DSKYF by Market Capitalization
Companies near Daiichi Sankyo Company Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Daiichi Sankyo Company Limited by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Daiichi Sankyo Company Limited Historical Marketcap From 2015 to 2025
Between 2015 and today, Daiichi Sankyo Company Limited's market cap moved from $11.25 Billion to $ 43.73 Billion, with a yearly change of 16.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $43.73 Billion | -27.84% |
| 2024 | $60.60 Billion | +25.27% |
| 2023 | $48.38 Billion | -18.29% |
| 2022 | $59.21 Billion | +28.43% |
| 2021 | $46.10 Billion | -25.66% |
| 2020 | $62.01 Billion | +58.62% |
| 2019 | $39.10 Billion | +91.62% |
| 2018 | $20.40 Billion | +45.44% |
| 2017 | $14.03 Billion | +28.43% |
| 2016 | $10.92 Billion | -2.94% |
| 2015 | $11.25 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Daiichi Sankyo Company Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $43.73 Billion USD |
| MoneyControl | $43.73 Billion USD |
| MarketWatch | $43.73 Billion USD |
| marketcap.company | $43.73 Billion USD |
| Reuters | $43.73 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.